Abstract
During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the progression of metastases in advanced disease or to eradicate possible micro-metastases in the adjuvant situation. This review aims to guide the reader along the paths of the progress made in hormonotherapy, chemotherapy and targeted molecular therapy. For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Enzyme Inhibitors / therapeutic use
-
Female
-
Humans
-
Paclitaxel / therapeutic use
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Tamoxifen / therapeutic use
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Antineoplastic Agents, Phytogenic
-
Enzyme Inhibitors
-
Tamoxifen
-
Receptor, ErbB-2
-
Trastuzumab
-
Paclitaxel